Avidity Biosciences
RNA
$24.36
Share price
2.22%
Change (1 day)
67.42%
Change (1 year)
Categories
Avidity Biosciences (RNA) - Total debt
Total debt on the balance sheet as of December 2023 : $9.85 M
According to Avidity Biosciences's latest financial reports the company's total debt is $9.85 M. A company’s total debt is the sum of all current and non-current debts.
Avidity Biosciences - Total debt on balance sheet (from 2019 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $9.85 M | -7.81% |
| 2022-12-31 | $10.68 M | -8.88% |
| 2021-12-31 | $11.72 M | 1150.43% |
| 2020-12-31 | $0.93 M | -81% |
| 2019-12-31 | $4.93 M | -52.18% |
| 2018-12-31 | $10.32 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $70.84 B | 718,992.57% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $22.93 B | 232,714.66% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | $1.39 B | 14,077.93% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | $2.22 B | 22,526.07% | 🇺🇸 USA |
 Fate Therapeutics
FATE | $0.10 B | 950.91% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | $0.18 B | 1,788.84% | 🇺🇸 USA |
 Acceleron Pharma XLRN | N/A | N/A | 🇺🇸 USA |
 Catalyst Pharmaceuticals CPRX | $3.55 M | -63.90% | 🇺🇸 USA |